机构:[1]Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Capital Med Univ, Beijing TongRen Hosp, Res Ward, Beijing, Peoples R China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Johnson & Johnson Consumer China Ltd, Shanghai, Peoples R China
Introduction: Relevant studies have demonstrated that glucocorticoids and antihistamines, such as budesonide and azelastine, are effective in the treatment of vasomotor rhinitis, with their combined use being more effective than that of a single drug. The aim of this study was to assess the improvement in the symptoms of patients following the combined administration of these drugs. Methods: We conducted a single-center randomized study on 42 patients. Participants were randomly treated with budesonide, levocabastine hydrochloride, or their combination for 2 weeks. The visual analog scale (VAS) score and levels of eosinophil cationic protein (ECP), histamine (HA), leukotriene B4 (LTB4), and vasoactive intestinal peptide (VIP) in nasal secretions were evaluated before and after treatment. Results: The symptoms of patients were improved in all 3 treatment groups compared with those before treatment. Following combined treatment, the improvement in symptoms of nasal obstruction, runny nose, nasal itching, and sneezing was much greater than those in the groups treated with budesonide or levocabastine hydrochloride alone (p = 0.04, 0.004, 0.005, 0.004, respectively). The decreased levels of these inflammatory mediators were significantly different between the different treatment groups. Conclusions: Budesonide or levocabastine hydrochloride alone improved the nasal symptoms of patients with vasomotor rhinitis and reduced the levels of ECP, HA, LTB4, and VIP in nasal secretions. However, their combination improved the symptoms of patients more significantly than each drug alone.
基金:
Beijing Nova Program [Z201100006820043]; National Key R&D program of China [2022YFC2504100]; Program for the Changjiang Scholars and Innovative Research team [IRT13082]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5-022]; Beijing Municipal Science & Technology Commission [Z211100002921057]; Capital's funds for health improvement and research [2022-1-1091]; Johnson & Johnson Consumer, Inc.
第一作者机构:[1]Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China[2]Beijing Inst Otolaryngol, Beijing Key Lab Nasal Dis, Beijing, Peoples R China[3]Capital Med Univ, Beijing TongRen Hosp, Res Ward, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Tan Ruyu,Meng Yifan,Wang Yang,et al.The Efficacy of Budesonide, Levocabastine, and Their Combination in Treatment of Vasomotor Rhinitis[J].ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY.2023,85(6):321-328.doi:10.1159/000533630.
APA:
Tan, Ruyu,Meng, Yifan,Wang, Yang,Zhang, Lili,Wang, Chengshuo&Zhang, Luo.(2023).The Efficacy of Budesonide, Levocabastine, and Their Combination in Treatment of Vasomotor Rhinitis.ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY,85,(6)
MLA:
Tan, Ruyu,et al."The Efficacy of Budesonide, Levocabastine, and Their Combination in Treatment of Vasomotor Rhinitis".ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY 85..6(2023):321-328